US 11,834,417 B2
Compositions for the treatment of hypertension and/or fibrosis
Karen Annette Duggan, New South Wales (AU)
Assigned to VECTUS BIOSYSTEMS LIMITED, New South Wales (AU)
Filed by Vectus Biosystems Limited, New South Wales (AU)
Filed on May 10, 2021, as Appl. No. 17/315,969.
Application 17/315,969 is a division of application No. 16/334,283, granted, now 11,053,202, previously published as PCT/AU2017/051027, filed on Sep. 21, 2017.
Claims priority of application No. 2016/03804 (AU), filed on Sep. 21, 2016.
Prior Publication US 2021/0284612 A1, Sep. 16, 2021
Int. Cl. C07D 233/64 (2006.01); C07D 241/04 (2006.01); A61P 9/00 (2006.01); A61P 13/12 (2006.01); A61P 11/00 (2006.01); C07D 233/90 (2006.01); C07D 401/06 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 403/04 (2006.01); C07D 417/04 (2006.01); C07D 413/04 (2006.01); C07D 413/06 (2006.01); C07D 403/06 (2006.01); C07D 407/04 (2006.01); C07D 417/06 (2006.01); C07D 407/06 (2006.01); C07D 409/06 (2006.01); C07D 409/04 (2006.01); A61P 1/16 (2006.01); A61P 9/12 (2006.01)
CPC C07D 233/64 (2013.01) [A61P 1/16 (2018.01); A61P 9/00 (2018.01); A61P 9/12 (2018.01); A61P 11/00 (2018.01); A61P 13/12 (2018.01); C07D 233/90 (2013.01); C07D 241/04 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07D 407/04 (2013.01); C07D 407/06 (2013.01); C07D 409/04 (2013.01); C07D 409/06 (2013.01); C07D 413/04 (2013.01); C07D 413/06 (2013.01); C07D 417/04 (2013.01); C07D 417/06 (2013.01)] 13 Claims
 
1. A compound of the formulae:

OG Complex Work Unit Chemistry
wherein:
X is selected from the group consisting of:

OG Complex Work Unit Chemistry
R1 to R9 are independently C, N, O or S;
R10 is independently selected from C1-6alkyl, halo, C0-6alkyl carboxylic acid, amino, hydroxy and C1-6alkoxy;
Y is A, CH2-A or CH=A;
A is selected from:

OG Complex Work Unit Chemistry
Z is selected from the group consisting of:

OG Complex Work Unit Chemistry
R11 is independently selected from halo, alkyl, hydroxy, amino and substituted amino;
R12, R14 and R15 are independently C, CH, CH2, O, N, NH or S;
R13 is C, CH, CH2, N, NH, C—CF3, CH—CF3 or C═O;
m is 0, 1, 2, 3, 4 or 5; and
n is 0, 1, 2, 3 or 4,
or a stereoisomer or pharmaceutically acceptable salt thereof.
 
11. A pharmaceutical composition comprising a compound, or a stereoisomer or pharmaceutically acceptable salt thereof, according to claim 1 and a pharmaceutically-acceptable excipient.